OR-AIRSHIP
23.9.2021 15:02:05 CEST | Business Wire | Press release
Apple’s newly introduced iOS 15 gives consumers greater control over how, when and where notifications arrive on their phone. If these new features are broadly adopted, current practices for notifications may not light up smartphone screens to immediately alert users. Since most iPhones will soon be running on iOS 15, it’s imperative that brands optimize their mobile engagement strategies to better serve their valuable app audiences with individualized preferences and exceptional, real-time experiences.
In order to accelerate brands’ efforts, customer engagement company Airship today announced the availability of Airship Preference Center — the industry’s first marketer-friendly preference center that makes it simple to create, manage and optimize customers’ opt-in choices without ongoing developer support or requisite app updates for the App Store or Google Play.
In addition to Airship Preference Center, the company’s day-one support for iOS 15 allows marketers to specify interruption levels for notifications — Passive, Active, Time Sensitive, or Critical — which iOS 15 uses to determine how they will be delivered. For example, a notification can be set to break through a ‘Focus’ mode to immediately alert a user, or it can be selected to arrive with an audible alert or not. Marketers can also use Airship to set relevance scores for notifications and to add rich media, which alongside user behavior, sets the order and prominence of a brand’s messages within the user-scheduled Notifications Summary.
“Mobile apps have been a lifeline for both businesses and consumers throughout the pandemic, offering faster purchasing, richer content and streamlined conveniences like curbside pickup. However, new user-centric notification controls mean marketers must be much clearer and more precise in the preference choices offered to customers to ensure the communications they receive are relevant and valued,” said Brett Caine, CEO and president, Airship. “Airship Preference Center brings unparalleled speed and flexibility to understand individual customer preferences, and fine-tune the experience with the full power of our platform to reach people when and where it matters most to them.”
Airship Preference Center is seamlessly integrated within Airship’s SaaS Customer Engagement Platform, enabling marketers to easily guide customers to their preference center through contextually triggered in-app messages or any number of cross-channel journeys for onboarding, loyalty enrollment, new subscription content and more. Airship’s easy-to-use composer enables marketers to quickly create multiple subscription lists spanning popular interests, topics or types of messages without the need for developer support.
For example, marketing messages like sales events and flash deals, or transactional messages like monthly statements or delivery/curbside pickup alerts, provide a range of urgency and convenience that expands consumer choice and improves long term opt-in retention as customers get what they want on each mobile channel. Marketers can automate combining opt-in selections with customers’ real-time mobile behaviors for hyper-personalized messaging. It’s also easy to track list opt-ins or review in-depth Performance Analytics reports to continually fine-tune and enhance options offered to customers.
“As pandemic restrictions lift and broad-scale travel resumes it’s absolutely vital that we connect our customers to the best values and broader inspiration to satisfy pent-up wanderlust,” said Dave McCormick, Managing Director - Product & Design, Alaska Airlines. “Airship’s Preference Center will provide an easy and efficient way to ensure marketing messages do not diminish the role our mobile app plays as a real-time travel companion, notifying customers of when they can check-in or if there happens to be a gate change.”
Register for Elevate 2021 , a virtual global forum for marketers and mobile product owners, taking place October 27-28, 2021. Attendees will learn about mobile-first best practices and insights driving innovation, business growth and deeper customer connections for dozens of leading brands around the world.
Airship in Independent Industry Analyst Evaluations
Airship was recently named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
Also, for the second consecutive year, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in Gartner’s 2020 Magic Quadrant for Mobile Marketing Platforms 1 , and received the highest Product Scores across all three Use Cases in Gartner’s 2020 Critical Capabilities for Mobile Marketing Platforms 2 , including the Acquisition, Engagement and Retention Use Cases.
1 Gartner “Magic Quadrant for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 26, 2020
2 Gartner “Critical Capabilities for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 29, 2020
Gartner Disclosure
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Airship
Thousands of the world’s leading brands rely on Airship to spark exceptional experiences with their customers through highly contextual and relevant interactions. Only Airship’s SaaS Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, rather than which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005184/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
